In addition, in mice with obesity, treatment with an NADPH oxidase inhibitor reduced ROS production in adipose tissue; attenuated the dysregulation of adipocytokines; and improved diabetes, hyperlipidemia, and hepatic steatosis. Here, FMO5 is linked to fatty liver disease.